Afrezza, a needle-free inhalable insulin spray, has been approved in India, offering a convenient and painless solution for managing diabetes.

The global prefilled syringes market share is projected to grow from US$ 6.69 Billion in 2022 to US$ 15.0 Billion by 2030, ...

Long-acting insulin helps people with diabetes maintain normal blood sugar levels throughout the day. Unlike short-acting insulin, it never peaks, keeping an even sugar level in your blood.

Impact of Trump’s tariffs on IT companies’ demand outlook, why kirana share in FMCG declining decoded, inward remittance data ...

Type 1 and type 2 diabetes require different approaches. Discover the 9 essential distinctions that affect daily management ...

A Pittsburgh firm is harnessing artificial intelligence to make it easier for military aircraft to land on ships at sea.

Hepatitis can damage your liver for years without symptoms. Learn how these viruses spread—and what truly protects your liver ...

The race is on to make the first oral weight loss medicines, but smaller US pharmacies may have already got there – if they ...

That’s because the level of investment needed to make the oral version a feasible alternative to injections would ... are looking to administer insulin with needle-free devices, and insulin ...

Detailed price information for Amphastar Pharma (AMPH-Q) from The Globe and Mail including charting and trades.

Recognized for contributions to address shortage of epinephrine injection, 0.1 mg/mL syringes RANCHO CUCAMONGA, CA / ACCESS Newswire / March 28, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) to ...